Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover				0.06 -	0.74 1,195.83%
cash conversion cycle				-4.24K -	271.70 106.41%
cash per share	0.07 -	0.28 316.48%	2.57 818.01%	10.79 319.56%	5.52 48.83%
company equity multiplier	-0.13 -	-0.21 66.45%	-0.70 230.53%	1.15 264.50%	1.19 3.88%
days of inventory outstanding				1.19K -	549.82 53.85%
days of payables outstanding				5.68K -	316.51 94.43%
days of sales outstanding				251.31 -	38.39 84.72%
dividend yield
ebit per revenue				-9.06 -	0.10 101.13%
ebt per ebit	1.01 -	1.08 7.12%	1.06 1.90%	0.98 7.71%	1.40 42.58%
effective tax rate	-0.08 -	-0.06 24.59%	0.00 100.98%	-0.00 762.35%	0.09 2,463.17%
enterprise value multiple	-62.41 -	-21.15 66.11%	-10.90 48.44%	-9.04 17.07%	20.65 328.35%
fixed asset turnover				2.73 -	59.40 2,073.57%
free cash flow per share	-0.23 -	-0.80 241.80%	-1.36 69.73%	-3.12 129.10%	0.16 105.09%
gross profit margin				0.87 -	0.93 7.84%
interest coverage	-10.62 -	-17.05 60.49%		-46.92 -
inventory turnover				0.31 -	0.66 116.68%
long term debt to capitalization	-1.43 -	-0.02 98.48%		0.01 -	0.00 62.99%
net income per ebt	1.08 -	1.06 1.83%	1.00 5.76%	1.00 0.45%	0.91 9.61%
net profit margin				-8.92 -	0.13 101.45%
operating cash flow per share	-0.23 -	-0.80 240.40%	-1.35 69.63%	-3.07 126.99%	0.18 105.77%
operating cycle				1.44K -	588.21 59.23%
operating profit margin				-9.06 -	0.10 101.13%
payables turnover				0.06 -	1.15 1,695.86%
pretax profit margin				-8.89 -	0.14 101.60%
price fair value	-32.46 -	-12.44 61.66%	-6.60 46.96%	6.35 196.14%	2.28 64.02%
receivables turnover				1.45 -	9.51 554.64%
return on assets	-4.60 -	-3.18 30.91%	-0.83 73.83%	-0.51 39.10%	0.10 118.79%
return on capital employed	10.35 -	-5.75 155.58%	-0.94 83.71%	-0.58 37.71%	0.09 115.26%
return on equity	0.58 -	0.67 15.00%	0.58 13.49%	-0.58 200.19%	0.11 119.52%
total debt to capitalization	-1.43 -	-0.02 98.48%		0.02 -	0.01 46.50%

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

5.19

22/11 21:00

Market Cap

361.25M

Beta: -

Volume Today

831.95K

Avg: -

Preview